Compare EP & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EP | ACOG |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.3M | 115.5M |
| IPO Year | N/A | N/A |
| Metric | EP | ACOG |
|---|---|---|
| Price | $3.22 | $5.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 37.4K | ★ 76.2K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,880,178.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.78 | $3.75 |
| 52 Week High | $6.90 | $11.54 |
| Indicator | EP | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 47.43 |
| Support Level | $2.98 | $5.20 |
| Resistance Level | $3.40 | $6.04 |
| Average True Range (ATR) | 0.21 | 0.44 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 50.82 | 46.06 |
Empire Petroleum Corp is a conventional oil and natural gas producer with a main focus in the United States onshore. The company possesses long-life, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana and Texas. It has production from operated and non-operated wells in Lea County in New Mexico, Bottineau, Renville, Burke, and McKenzie Counties in North Dakota, Richland County in Montana, St. Landry, Beauregard Parishes in Louisiana and Houston, Leon and Madison Counties in Texas.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.